Government to make decision on Cystic Fibrosis medicine Orkambi
HSE management is to consider a proposal from the drug’s manufacturer, Vertex Pharmaceuticals
Ministers are to decide on the affordability of cystic fibrosis drug Orkambi this month.
HSE management is to consider a proposal from the drug’s manufacturer, Vertex Pharmaceuticals, in coming weeks after a previous offer was deemed too expensive to fund.
The company had demanded €159,000 per patient, per year, which would cost the HSE €391 million over five years.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
HSE chief: Ireland in ‘final countdown’ stage of vaccinations
The Health Service Executive is considering closing some mass vaccination centres in autumn as the uptake in jabs continues
Lucinda Creighton: We should harness Olympic glory to tackle our weight crisis
The incredible efforts of our Olympians in Tokyo are in sharp contrast to the fact that we are now the second most obese nation in the EU
Thérapie to offer egg freezing service to women in their 20s
The group best known for providing cosmetic Botox and laser hair removal has invested €10 million in three new fertility clinics